MAYNE PHARMA LAUNCHES DOXYCYCLINE IR CAPSULES IN THE US, GENERIC...

MAYNE PHARMA LAUNCHES DOXYCYCLINE IR CAPSULES IN
THE US, GENERIC MONODOX®

16 March 2018, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to
announce the launch of doxycycline monohydrate immediate release (IR) capsules (50mg, 75mg
and 100mg) in the United States. Doxycycline IR capsules are a generic alternative to Monodox®,
a tetracycline-class antibacterial indicated for the treatment of a number of infections, including
adjunctive therapy in severe acne.
Mayne Pharma’s CEO Scott Richards said, “This launch will further broaden Mayne Pharma’s
dermatology portfolio of branded and generic products. Mayne Pharma is committed to helping
patients and physicians cost effectively manage various skin conditions including acne and
psoriasis.”
Mayne Pharma directly markets more than 55 products and has a growing pipeline of around 30
drug products targeting US markets with IQVIA sales greater than US$5 billion. According to IQVIA,
annual US sales of doxycycline IR capsules were approximately US$30 million for the 12 months
ending 31 January 2018.

For further information contact:
Lisa Pendlebury +61 419 548 434, [email protected]